Loading...
XNAS
ANIP
Market cap1.64bUSD
Oct 08, Last price  
71.98USD
1D
0.07%
1Q
-12.29%
Jan 2017
18.74%
IPO
-66.11%
Name

ANI Pharmaceuticals Inc

Chart & performance

D1W1MN
XNAS:ANIP chart
P/E
20.89
P/S
1.85
EPS
3.45
Div yield, %
—
Shrs. gr., 5y
12.15%
Rev. gr., 5y
33.48%
Revenues
883m
+43.78%
14,438,621493,0543,780,8291,258,0542,474,237435,1602,300,73630,082,00055,970,00076,322,000128,622,000176,842,000201,576,000206,547,000208,475,000216,136,000316,385,000486,816,000614,376,000883,366,000
Net income
78m
P
2,791,273-7,584,435-17,425,178-47,527,768-46,196,216-51,608,504-27,717,739301,00028,747,00015,375,0003,934,000-1,076,00015,494,0006,094,000-22,548,000-42,603,000-47,896,00018,779,000-18,522,00078,337,000
CFO
185m
+189.34%
-4,996,735739,992-15,535,932-18,430,910-40,097,506-47,870,103-25,283,020-5,484,00022,033,00017,264,00027,472,00039,419,00067,074,00045,631,00015,267,0003,322,000-31,203,000118,959,00064,017,000185,225,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Key people

Patrick Walsh
Independent Chairman of the Board · since 2020
Nikhil Lalwani
President, Chief Executive Officer, Director · since 2020
Stephen Carey
Chief Financial Officer, Senior Vice President - Finance · since 2022
Krista Davis
Chief Human Resources Officer, Senior Vice President · since 2022
Meredith Cook
Senior Vice President, General Counsel, Corporate Secretary · since 2022
Chad Gassert
Senior Vice President - Corporate Development and Strategy · since 2021
Ori Gutwerg
Senior Vice President - Generics · since 2021
Christopher Mutz
Senior Vice President, Head of Rare Diseases · since 2022
Thomas Rowland
Senior Vice President, Head of Established Brands · since 2023
Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations · since 2021
Thomas Haughey
Independent Director · since 2018
Matthew Leonard
Independent Director · since 2023
Antonio Pera
Independent Director · since 2020
Renee Tannenbaum
Independent Director · since 2022
Jeanne Thoma
Independent Director · since 2020
URL
https://www.anipharmaceuticals.com/
IPO date
May 04, 2000
Employees
600
Domiciled in
US
Incorporated in
US
Headquarters & legal address
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT